PMC

(A) Prevalence of metabolic syndrome in different age subgroups. Age subgroups 1 to 6 referred to the followings: age ≤ 25 years, 25 years < age ≤ 35 years, 35 years < age ≤ 45 years, 45 years < age ≤ 55 years, 55 years < age ≤ 65 years, age > 65 years. *Significant difference between genders with P < 0.01. (B) Prevalence of metabolic syndrome in different total bilirubin (TBIL) subgroups. TBIL subgroups 1 to 4 in male referred to the followings: TBIL ≤ 9.90 μmol/L, 9.90 μmol/L < TBIL ≤ 12.90 μmol/L, 12.90 μmol/L < TBIL ≤ 16.80 μmol/L, TBIL > 16.80 μmol/L. TBIL subgroups 1 to 4 in female referred to the followings: TBIL ≤ 8.00 μmol/L, 8.00 μmol/L < TBIL ≤ 10.30 μmol/L, 10.30 μmol/L < TBIL ≤ 13.40 μmol/L, TBIL > 13.40 μmol/L. *significant difference between genders with P < 0.01. (C) Prevalence of metabolic syndrome in different gamma glutamyltransferase (GGT) subgroups. GGT subgroups 1 to 4 in male referred to the followings: GGT ≤ 20.00U/L, 20.00U/L < GGT ≤ 30.00U/L, 30.00U/L < GGT ≤ 48.00U/L, GGT > 48.00U/L. GGT subgroups 1 to 4 in female referred to the followings: GGT ≤ 11.00U/L, 11.00U/L < GGT ≤ 15.00U/L, 15.00U/L < GGT ≤ 21.00U/L, GGT > 21.00U/L. *significant difference between genders with P < 0.01. (D) Prevalence of metabolic syndrome in different alanine aminotransferase (ALT) subgroups. ALT subgroups 1 to 4 in male referred to the followings: ALT ≤ 17.00U/L, 17.00U/L < ALT ≤ 24.00U/L, 24.00U/L < ALT ≤ 34.00U/L, ALT > 34.00U/L. ALT subgroups 1 to 4 in female referred to the followings: ALT ≤ 13.00U/L, 13.00U/L < ALT ≤ 16.00U/L, 16.00U/L < ALT ≤ 22.00U/L, ALT > 22.00U/L. *significant difference between genders with P < 0.01.

Cumulative incidence of events in patients with psoriasis and CAD according to TBIL tertiles
(A) Cumulative incidence of MACCEs in patients with psoriasis and CAD according to TBIL tertiles (p = 0.011). Higher vs. lower tertiles (p = 0.018). Higher vs. middle tertiles (p = 0.839).
(B) Cumulative incidence of all-cause death in patients with psoriasis and CAD according to TBIL tertiles (p = 0.069).
(C) Cumulative incidence of cardiac death in patients with psoriasis and CAD according to TBIL tertiles (p = 0.076).
(D) Cumulative incidence of non-fatal myocardial infarction in patients with psoriasis and CAD according to TBIL tertiles (p = 0.088).
(E). Cumulative incidence of non-fatal ischemic stroke in patients with psoriasis and CAD according to TBIL tertiles (p = 0.392).
(F) Cumulative incidence of unplanned revasculation in patients with psoriasis and CAD according to TBIL tertiles (p = 0.080).
(G) Cumulative incidence of rehospitalization because of heart failure or angina in patients with psoriasis and CAD according to TBIL tertiles (p = 0.781). Abbreviation: MACCE, major adverse cardiovascular and cerebrovascular event; CAD, coronary artery disease; TBIL, Total bilirubin.

The differences of the increase-folds of TBIL, the increase-folds of CA19-9 and the ratio of increase-folds of CA19-9 to increase-folds of TBIL of different etiologies of MOJ and BOJ (median value ± interquartile range): In MOJ, the elevation of TBIL of cholangiocarcinoma was significantly higher than that of periampullary adenocarcinooma; In BOJ, the elevation of TBIL in PSC was significantly higher than that of cholelethiasis, IRSC and inflammatory stricture. P <0.05; **, P <0.01(Tukey's Multiple Comparison Test)

Kaplan‐Meier curves for mechanical ventilation‐free survival probability during hospitalisation in patients with different levels of (A) ALT, (B) AST and (C) TBIL. ALT 0: ALT ≤40 U/L; ALT 1: 40‐120 U/L; ALT 2: ≥120 U/L. AST 0: AST ≤40 U/L; AST 1: 40‐120 U/L; AST 2: ≥120 U/L. TBIL 0: ≤21 μmol/L; TBIL 1: 21‐63 μmol/L; TBIL 2: ≥63 μmol/L. 0*: ALT or AST or TBIL ≤ ULN; 1*: ALT or AST or TBIL: ULN‐3ULN; 2*: ALT or AST or TBIL ≥ 3ULN